Ann: Alterity to Present New Data at the AAN 2024 Annual Meeting, page-9

Hi Stockman ... very nice post.

I certainly agree with you on all the points you make here.

I would highlight a couple of things here, as I read it ...

1. The American Academy of Neurology is a BIG deal. Some would argue that it is the most prestigious Neurology Academy in the world. Please note it has more than 40,000 members, all specialists in this field. This is a big deal, and as @Stockman highlights ... “Something else that got me excited was the 3 Team Members Presenting”. It is clear that the AAN selection team likes something it has seen in ATH’s trials. In my experience, in events at this level, there are more presentations rejected, than those accepted.

2. The release states ... “we are thrilled to be presenting ... new baseline biomarker data on ATH434 from our ongoing Phase 2randomized, double blind clinical trial in multiple system atrophy (MSA)”. So, what does this mean? Are they going to do a data cut, and do a significant analysis, ready for this meeting? I would expect that they would need to have some sort of ‘clearance’ from the FDA for this to occur. This is a highly controlled trial. The ATH team is leaving little scope for error. This Ph2 trial is a randomised trial, ATH434 vs placebo, with QuadrupleMasking !!! Regardless, I have to think the ATH team have some ‘interesting’ news to share ... and if this is the case, then hold on to your hats.

Note: This trial is looking at all the key markers that Big Pharma will want to see. These include, but are not limited to:

1. change in iron content

2. change in aggregating alpha-Synuclein levels (this is the one I’m particularly waiting to see)

3. change in Neurofilament Light Chain Levels

... and I did say that the ‘team was leaving little scope for error’ ... this trial is open across 23 sites, in 7 countries !!!

I suspect that things are about to get very interesting ... one way or the other. GLTAH

Opinion only